EGFR and neoplasm: In a previous report, the Ru(II)-arene complex [Ru(η6-p-cymene)Cl2] (RAPTA-C) was tested for efficacy in combination with the epidermal growth factor receptor inhibitor erlotinib, demonstrating an efficient anti-angiogenic and anti-tumor activity [34].